From: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials
Excluded Trial | Patient Inclusion | Number of Patients/Centres | Intervention | Control | Follow Up Duration | Outcomes | Reason for Exclusion |
---|---|---|---|---|---|---|---|
Prevention of Post-Op Afib | |||||||
Saenen et al. Eur Heart J 2013 [Abstract] [38] | Post CABG | 40/single | Peri-operative Colchicine | Placebo | 1Â hour post CABG | Right Atrial Appendage Biopsy Pathology | Only pathology data provided |
Nidorf & Thompson Am J Card 2007 [39] | Stable CAD | 64/single | Colchicine | Control | 4Â weeks | C-reactive protein | Not randomized |
Freed et al. Am J Card 1995 [40] | Post PTCA | 5/single | Cochicine + Enalapril + Lovastatin | n/a | 5 months | Death, MI, revasc. | Not randomized |
Rab et al. JACC 1991 [41] | Post BMS PTCA | 29/single | Colchicine + gluco-corticoids | Gluco-corticoids | 4 months | Coronary artery aneurysm | Not randomized |
Judkins et al. Heart Lung Circ 2011 [Abstract] [42] | Stable CAD | 50/single | Colchicine | Control | 6Â months | C-reactive protein; flow mediated dilation | Cross over RCT |
Luo & Yang. Hong Kong Med J 2001 [Abstract] [43] | Acute stroke | n/a | Colchicine, Cyclo-phosphamide plus Magnesium | Control | n/a | n/a | Combined intervention |
Xu et al. West China Med J 1999 [Chinese] [44] | Acute stroke | 64/single | Colchicine and Cyclo-phosphamide | Control | 3Â months | Neurological outcomes | Combined intervention |
Liu et al. Chin J Geriat Cardiovasc Cerebrovasc Dis 2002 [Chinese] [45] | Acute stroke | 325/multi | Colchicine and Cyclo-phosphamide | Control | 3Â months | Neurological outcomes, serum enolase, adverse events | Combined intervention |